These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 9361394

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects of sex steroids on proliferation in normal mammary tissue.
    Söderqvist G.
    Ann Med; 1998 Dec; 30(6):511-24. PubMed ID: 9920352
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.
    L'hermite M, Simoncini T, Fuller S, Genazzani AR.
    Maturitas; 2008 Dec; 60(3-4):185-201. PubMed ID: 18775609
    [Abstract] [Full Text] [Related]

  • 9. Progestins and bone.
    Thijssen JH.
    Zentralbl Gynakol; 1997 Dec; 119 Suppl 2():70-4. PubMed ID: 9361396
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
    Menendez JA, Oza BP, Colomer R, Lupu R.
    Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
    Genazzani AR, Gadducci A, Gambacciani M.
    Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
    [Abstract] [Full Text] [Related]

  • 14. Cyproterone, norethindrone, medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin-like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the estrogen receptor.
    Milewicz T, Kolodziejczyk J, Krzysiek J, Basta A, Sztefko K, Kurek S, Stachura J, Gregoraszczuk EL.
    Gynecol Endocrinol; 2002 Aug; 16(4):319-29. PubMed ID: 12396561
    [Abstract] [Full Text] [Related]

  • 15. Estrogen and estrogen plus progestin act directly on the mammary gland to increase proliferation in a postmenopausal mouse model.
    Raafat AM, Li S, Bennett JM, Hofseth LJ, Haslam SZ.
    J Cell Physiol; 2001 Apr; 187(1):81-9. PubMed ID: 11241352
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Treatment of the menopause: estrogens and breast cancer].
    Gorins A.
    Rev Fr Gynecol Obstet; 1985 Mar; 80(4):211-4. PubMed ID: 3992121
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Hormone replacement therapy and cancer.
    Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
    [Abstract] [Full Text] [Related]

  • 20. Hormone therapy and breast cancer risk.
    Foidart JM, Desreux J, Pintiaux A, Gompel A.
    Climacteric; 2007 Oct; 10 Suppl 2():54-61. PubMed ID: 17882674
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.